Search results
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 8 hours agoIt's important to note, Sanofi isn't helping Novavax commercialize in 2024. Nuvaxovid is available...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 9 hours agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Healthy Returns: What we know about the next round of Covid vaccines
CNBC· 1 day agoA new round of Covid shots will likely reach Americans in the coming months. Here's what we know...
Moderna's Combo Flu/Covid Shot Topped Rivals From Sanofi, GSK
Investor's Business Daily· 4 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
COVID shots should target JN.1 variant in fall 2024 campaign, US FDA says
StreetInsider· 6 days agoThe Food and Drug Administration's advisory is in line with European and World Health Organization recommendations and comes after the agency's advisers on Wednesday overwhelmingly backed the ...
Novavax (NASDAQ:NVAX) Shares Gap Down to $19.56
ETF DAILY NEWS· 5 days agoShares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $19.56, but opened at $18.79. & ...
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Benzinga via AOL· 6 days agoThe submission is based on FDA guidance, which advised that COVID-19 vaccines should be updated to a...
Moderna’s combo COVID and flu vaccine works better than stand-alone shots on the market, study finds
Market Watch· 4 days agoexperimental combination COVID and flu vaccine triggered better immune responses than stand-alone...
There's another COVID variant you should know about: KP.3 now makes up 25% of COVID cases
USA Today· 5 days agoThe Centers for Disease Control and Prevention data shows that a new COVID variant, the KP.3...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 7 days agoThe following compilation represents a selection of stocks featured on our website that reached new 52-week high levels during the current week. Protagonist is a clinical-stage biopharmaceutical ...